Thought leadership articles

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With […]

At Dewpoint, we are working to unlock the full potential of condensate science to discover and develop life-changing treatments for […]

At Dewpoint we are embracing all forms of science from biology, chemistry and physics to data science and artificial intelligence […]

“I believe we are on our way towards a MYC c-mod, says Bede Portz, Dewpoint’s ovarian cancer program lead. Our […]

Colorectal cancer is the third most common cancer globally and the second leading cause of cancer-related deaths worldwide. We at […]

Rare diseases are a core pillar of Dewpoint’s development portfolio. With condensates playing fundamental roles in cellular biology and as […]

In the final installment of our 5th anniversary ‘conversation with’ series, we spoke to leading condensate scientist and Dewpoint co-founder […]

As we start a new year, we continue our series of conversations with our board members to hear their reflections […]

“A discovery such as condensates, which is so fundamental to cellular biology, will surely have a major impact on how […]

“I think Dewpoint’s team is on a very promising pathway” says Dr. Eckhardt, EVP at Bayer. As we celebrate our […]

Boston, Massachusetts, March 26, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Boston, Massachusetts, January 29, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ConcertAI’s Clinico-Genomic Solutions  Boston, MA and […]

BOSTON, Massachusetts, December 4, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today […]